Abstract Zinc-α2-glycoprotein (ZAG), encoded by the AZGP1 gene, is a major
histocompatibility complex I molecule and a lipid-mobilizing factor. ZAG has been …

Clinical and experimental data hints that prolonged and repeated epileptic seizures can
lead to molecular, biochemical, metabolic, and structural changes in the brain, a continuous …

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a group of antidiabetic
medications with a favourable cardiovascular, renal and overall safety profile. Given the …

Background Worldwide, over 10 million individuals suffer from drug-resistant epilepsy. New
therapeutic strategies are needed to address this debilitating disease. Inhibition of sodium …

Evidence supports that the gut microbiota and bacteria-dependent metabolites influence the
maintenance of epileptic brain activity. However, the alterations in the gut microbiota …

The choroid plexus plays a central role in the regulation of the microenvironment of the
central nervous system by secreting the majority of the cerebrospinal fluid and controlling its …

The hippocampus exhibits a wide range of epilepsy-related abnormalities and is situated in
the mesial temporal lobe, where limbic seizures begin. These abnormalities could affect …

The hippocampal formation is crucial for the generation and regulation of several brain
functions, including memory and learning processes; however, it is vulnerable to …

Abstract Background Zinc-α2-glycoprotein (ZAG) is a 42-kDa protein reported as an anti-
inflammatory adipocytokine. Evidences from clinical and experimental studies revealed that …

Introduction This study aims to evaluate the effects of sodium‐glucose cotransporter 1
inhibitors (SGLT1i) and sodium‐glucose cotransporter 2 inhibitors (SGLT2i) on …